Grade II/III Glioma
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas (NCT02766270) | Beijing Tiantan Hospital | 2016-09-26 |
Track Grade II/III Glioma automatically
Every clearance here is in the API, with alerts when new ones post.